<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00705185</url>
  </required_header>
  <id_info>
    <org_study_id>2007-P-002525</org_study_id>
    <nct_id>NCT00705185</nct_id>
  </id_info>
  <brief_title>Exploring a Potential Blood Test to Diagnose Major Depressive Disorder</brief_title>
  <acronym>Bio-TestMDD</acronym>
  <official_title>Exploring Potential Serum/Plasma-Based Biomarkers as a Test for Major Depressive Disorder Diagnostics (&quot;Bio-Test MDD&quot;)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Precision Human Biolaboratories</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Cambridge Health Alliance</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Connecticut</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Vanderbilt University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Psychiatric Medicine Associates, L.L.C.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Massachusetts General Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to develop a blood test for major depression and measure the&#xD;
      effects of ziprasidone monotherapy on these markers.&#xD;
&#xD;
      Specific Aim: Using a multiplex biomarker assay we will measure levels of 16 biomarkers in&#xD;
      patients with MDD enrolled in this ancillary study (adjunct to study NCT00555997) and compare&#xD;
      these results to those of healthy controls&quot; (defined as research subjects who have not met&#xD;
      criteria for any lifetime Axis-I disorder (DSM-IV)) from an existing dataset at PHB.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This proposed study will be an ancillary study to clinical trial NCT00555997&#xD;
      (www.clinicaltrials.gov) entitled: &quot;A 12-Week, Randomized, Double-Blind, Placebo-Controlled,&#xD;
      Parallel-Sequential Trial of Ziprasidone as Monotherapy for Major Depressive Disorder&quot;&#xD;
      (MDD).&quot; Precision Human Biolaboratory (&quot;PHB&quot;) is attempting to develop a proprietary blood&#xD;
      test intended to potentially serve as a biological marker (&quot;bio-marker&quot;) for MDD.&#xD;
      Specifically, PHB's research team will employ a unique approach towards developing a&#xD;
      diagnostic test for MDD: measures from multiple blood-based biological markers will be&#xD;
      obtained from patients with MDD and then analyzed with the use of several interrelated&#xD;
      algorithms in order to derive a single biological measure (&quot;bio-marker&quot;) with a high&#xD;
      predictive value for MDD. PHBs' test panel of blood-based biological markers will consist of&#xD;
      a number of cytokines, stress related hormones, and binding proteins that have each been&#xD;
      linked to MDD. This innovative test panel is expected to provide general practice physicians&#xD;
      with a tool to more accurately identify and classify patients with MDD which, in turn, could&#xD;
      potentially , allow for the more effective monitoring of pharmacotherapy (antidepressant drug&#xD;
      therapy). Thus, the development of a highly reliable biomarker for MDD could improve the&#xD;
      standard of care for depression.&#xD;
&#xD;
      For this ancillary study, 120 antidepressant-free outpatients with MDD who have been deemed&#xD;
      eligible to participate in trial NCT00555997 will be recruited from participating centers.&#xD;
      Participating subjects will undergo a blood draw during the baseline visit for NCT00555997.&#xD;
      Values obtained will be compared with those of &quot;healthy controls&quot; (defined as research&#xD;
      subjects who have not met criteria for any lifetime Axis-I disorder (DSM-IV)) from an&#xD;
      existing dataset at PHB.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2008</start_date>
  <completion_date type="Actual">June 2010</completion_date>
  <primary_completion_date type="Actual">June 2010</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>16 Biological Markers; Group comparison between adults with Major Depressive Disorder and healthy controls</measure>
    <time_frame>Screen visit</time_frame>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Major Depressive Disorder</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <description>Adults with Major Depressive Disorder- as defined by the criteria in the DSM-IV</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <description>Healthy Controls- research subjects who have not met criteria for any lifetime Axis-I disorder (DSM-IV)</description>
  </arm_group>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      serum, plasma&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Adults with Major Depressive Disorder (DSM-IV)&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Age 18-65.&#xD;
&#xD;
          -  Written informed consent.&#xD;
&#xD;
          -  MDD, current according to the fourth version of the Diagnostic and Statistical Manual&#xD;
             for Mental Disorders (DSM-IV) as diagnosed by the Mini International Neuropsychiatric&#xD;
             Interview (MINI; Sheehan et al, 1998).&#xD;
&#xD;
          -  Quick Inventory of Depressive Symptomatology - Self-Rated (QIDS-SR- Trivedi et al,&#xD;
             2004) score of at least 10 at both screen and baseline visits.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant women.&#xD;
&#xD;
          -  Women of child bearing potential who are not using a medically accepted means of&#xD;
             contraception (to include oral contraceptive or implant, condom, diaphragm,&#xD;
             spermicide, intrauterine device, tubal ligation, or a partner with vasectomy).&#xD;
&#xD;
          -  Treatment with antidepressants for 2 weeks prior to the screen visit. If interested in&#xD;
             discontinuing their current medication, potential participants must discuss this&#xD;
             possibility with the prescribing physician. Study doctors will not implement any form&#xD;
             of treatment washout.&#xD;
&#xD;
          -  Patients who no longer meet DSM-IV criteria for MDD during the baseline visit, or&#xD;
             patients who demonstrate a 25% or greater reduction in QIDS-SR scores, screening to&#xD;
             baseline.&#xD;
&#xD;
          -  Serious suicide or homicide risk, as assessed by the evaluating clinician or a score&#xD;
             of 4 on the third item of the HAM-D.&#xD;
&#xD;
          -  Unstable medical illness including cardiovascular, hepatic, renal, respiratory,&#xD;
             endocrine, neurological, or hematological disease.&#xD;
&#xD;
          -  Patients who meet criteria for alcohol or substance dependence, active within the last&#xD;
             month.&#xD;
&#xD;
          -  Any bipolar disorder (current or past).&#xD;
&#xD;
          -  Any psychotic disorder (current or past).&#xD;
&#xD;
          -  Psychotic features in the current episode or a history of psychotic features.&#xD;
&#xD;
          -  History of a seizure disorder.&#xD;
&#xD;
          -  Clinical or laboratory evidence of untreated hypothyroidism.&#xD;
&#xD;
          -  Patients requiring excluded medications (see table 1 for details).&#xD;
&#xD;
          -  Prior course of ziprasidone, or intolerance to ziprasidone at any dose.&#xD;
&#xD;
          -  Any investigational psychotropic drug within the last 3 months.&#xD;
&#xD;
          -  Patients with significant cardiac conduction problems on screening electrocardiogram&#xD;
             such as atrial fibrillation, atrial flutter, atrio-ventricular block, prolonged or&#xD;
             abnormal QTc interval (i.e. QTc&gt;450msec), or prolonged QRS interval.&#xD;
&#xD;
          -  Patients who have suffered a myocardial infarction within the past 12 months, with&#xD;
             uncompensated heart failure, or a history of QTc prolongation.&#xD;
&#xD;
          -  Patients with abnormal serum potassium or magnesium levels upon screening.&#xD;
&#xD;
          -  Patients currently taking other drugs that prolong the QTc including dofetilide,&#xD;
             sotalol, quinidine, class Ia antiarrhythmics, class III antiarrhythmics, mesoridazine,&#xD;
             thioridazine, chlorpromazine, droperidol, pimozide, sparfloxacin, gatifloxacin,&#xD;
             moxifloxacin, halofantrine, mefloquine, pentamidine, arsenic trioxide, levomethadyl&#xD;
             acetate, dolasetron methylate, probucol or tacrolimus.&#xD;
&#xD;
          -  Patients who have failed to experience significant clinical improvement following 3 or&#xD;
             more antidepressant trials of adequate duration (at least 6 weeks) and dose (minimal&#xD;
             effective doses defined as: fluoxetine, paroxetine, citalopram 20mg; sertraline,&#xD;
             fluvoxamine 50mg, escitalopram 10mg, paroxetine CR 25mg, venlafaxine 75mg, duloxetine&#xD;
             60mg, bupropion 150mg, 15mg of mirtazapine, trazodone or nefazodone 300mg).&#xD;
&#xD;
          -  The presence of Addison's or Cushing's disease.&#xD;
&#xD;
          -  The presence of rheumatoid arthritis, or systemic lupus erythematosus.&#xD;
&#xD;
          -  The regular use of non-steroidal anti-inflammatory medications or oral steroids.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>George I Papakostas, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Connecticut Health Center</name>
      <address>
        <city>Farmington</city>
        <state>Connecticut</state>
        <zip>06030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Psychiatric Medicine Associates, L.L.C.</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60025</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hosptial</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cambridge Health Alliance</name>
      <address>
        <city>Cambridge</city>
        <state>Massachusetts</state>
        <zip>02139</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2010</verification_date>
  <study_first_submitted>June 23, 2008</study_first_submitted>
  <study_first_submitted_qc>June 23, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 25, 2008</study_first_posted>
  <last_update_submitted>June 7, 2010</last_update_submitted>
  <last_update_submitted_qc>June 7, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 8, 2010</last_update_posted>
  <responsible_party>
    <name_title>George I. Papakostas, M.D.</name_title>
    <organization>Massachusetts General Hospital</organization>
  </responsible_party>
  <keyword>Major Depressive Disorder</keyword>
  <keyword>Blood Test</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder, Major</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

